peripheral nervous system diseases

Summary

Summary: Diseases of the peripheral nerves external to the brain and spinal cord, which includes diseases of the nerve roots, ganglia, plexi, autonomic nerves, sensory nerves, and motor nerves.

Top Publications

  1. ncbi Neurological complications of HIV infection
    Justin C McArthur
    HIV Neurosciences Program, Johns Hopkins University, Baltimore, MD, USA
    Lancet Neurol 4:543-55. 2005
  2. ncbi Chemotherapy-induced peripheral neuropathies: from clinical relevance to preclinical evidence
    David Balayssac
    INSERM U766, Laboratoire de Toxicologie Faculté de Pharmacie, Place Henri Dunant, F 63000 Clermont Ferrand, France
    Expert Opin Drug Saf 10:407-17. 2011
  3. ncbi EFNS guidelines on the use of skin biopsy in the diagnosis of peripheral neuropathy
    G Lauria
    Immunology and Muscular Pathology Unit, Department of Clinical Neurosciences, National Neurological Institute Carlo Besta, Milan, Italy
    Eur J Neurol 12:747-58. 2005
  4. ncbi Mechanisms in cancer-chemotherapeutic drugs-induced peripheral neuropathy
    Amteshwar Singh Jaggi
    Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala 147002, Punjab, India
    Toxicology 291:1-9. 2012
  5. ncbi Chemotherapy-induced neuropathy
    Anthony J Windebank
    Division of Neuroscience, Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    J Peripher Nerv Syst 13:27-46. 2008
  6. ncbi The spectrum of neuropathy in diabetes and impaired glucose tolerance
    C J Sumner
    Department of Neurology, The Johns Hopkins University, Baltimore, MD, USA
    Neurology 60:108-11. 2003
  7. ncbi Selective loss of spinal GABAergic or glycinergic neurons is not necessary for development of thermal hyperalgesia in the chronic constriction injury model of neuropathic pain
    E Polgar
    Spinal Cord Group, Institute of Biomedical and Life Sciences, West Medical Building, University of Glasgow, Glasgow G12 8QQ, UK
    Pain 104:229-39. 2003
  8. ncbi Beyond neurons: evidence that immune and glial cells contribute to pathological pain states
    Linda R Watkins
    Department of Psychology and the Center for Neuroscience, University of Colorado at Boulder, Boulder, Colorado
    Physiol Rev 82:981-1011. 2002
  9. pmc Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: evidence for mitochondrial dysfunction
    Sarah J L Flatters
    Anaesthesia Research Unit, McGill University, Montreal, Que, Canada
    Pain 122:245-57. 2006
  10. ncbi Increased prevalence of impaired glucose tolerance in patients with painful sensory neuropathy
    J R Singleton
    Division of Neuromuscular Disease, Department of Neurology, University of Utah, Salt Lake City, Utah 84132, USA
    Diabetes Care 24:1448-53. 2001

Research Grants

  1. 2010 Neuropathy Physicians Conference
    TINA MARIE TOCKARSHEWSKY; Fiscal Year: 2010
  2. REHABILITATION OF MICRONEUROVASCULAR GRAFTS IN OLD RATS
    Lisa Larkin; Fiscal Year: 2000
  3. PERIPHERAL NERVE INJURY AND RECOVERY OF FUNCTION
    Richard Nichols; Fiscal Year: 2004
  4. HIV GP120 EFFECTS ON NEUROTRANSMISSION
    RICHARD ZIEGLER; Fiscal Year: 1993
  5. Metabolomic Signatures in ALS
    Merit Cudkowicz; Fiscal Year: 2005
  6. Diagnostic and Surrogate Markers for ALS
    LISA PAIGE; Fiscal Year: 2005
  7. Defibrotide for the treatment of severe hepatic veno-cc*
    Paul Richardson; Fiscal Year: 2007
  8. 2007 International Peripheral Nerve Society Meeting at Snowbird, Utah
    A Smith; Fiscal Year: 2007
  9. Peripheral neurotoxicity by the HIV-1 coat protein gp120
    Ahmet Hoke; Fiscal Year: 2007
  10. PERIPHERAL NEUROPATHY, SENSORIMOTOR FUNCTIONS & BALANCE
    James Richardson; Fiscal Year: 2004

Detail Information

Publications276 found, 100 shown here

  1. ncbi Neurological complications of HIV infection
    Justin C McArthur
    HIV Neurosciences Program, Johns Hopkins University, Baltimore, MD, USA
    Lancet Neurol 4:543-55. 2005
    ..The sensory neuropathies associated with HIV infection are a major cause of morbidity; incidence may be increased by the toxic effects of specific antiretroviral drugs within the peripheral nervous system...
  2. ncbi Chemotherapy-induced peripheral neuropathies: from clinical relevance to preclinical evidence
    David Balayssac
    INSERM U766, Laboratoire de Toxicologie Faculté de Pharmacie, Place Henri Dunant, F 63000 Clermont Ferrand, France
    Expert Opin Drug Saf 10:407-17. 2011
    ..CIPN can profoundly affect the quality-of-life, often compelling clinicians to lower the chemotherapy regimen, consequently limiting therapeutic efficacy...
  3. ncbi EFNS guidelines on the use of skin biopsy in the diagnosis of peripheral neuropathy
    G Lauria
    Immunology and Muscular Pathology Unit, Department of Clinical Neurosciences, National Neurological Institute Carlo Besta, Milan, Italy
    Eur J Neurol 12:747-58. 2005
    ..Training in an established cutaneous nerve laboratory is recommended before using skin biopsy as a diagnostic tool in peripheral neuropathies. Quality control at all levels is mandatory...
  4. ncbi Mechanisms in cancer-chemotherapeutic drugs-induced peripheral neuropathy
    Amteshwar Singh Jaggi
    Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala 147002, Punjab, India
    Toxicology 291:1-9. 2012
    ..The present review elaborates the role of all these individual targets in the pathogenesis of anticancer agents-induced neuropathic pain to develop effective therapeutic modalities for pain management...
  5. ncbi Chemotherapy-induced neuropathy
    Anthony J Windebank
    Division of Neuroscience, Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    J Peripher Nerv Syst 13:27-46. 2008
    ..In patients with neuropathy, restorative approaches have not been well established. Symptomatic and other management are necessary to maintain and improve quality of life...
  6. ncbi The spectrum of neuropathy in diabetes and impaired glucose tolerance
    C J Sumner
    Department of Neurology, The Johns Hopkins University, Baltimore, MD, USA
    Neurology 60:108-11. 2003
    ..To compare the neuropathy associated with impaired glucose tolerance (IGT) and diabetes mellitus (DM) determined by oral glucose tolerance testing (OGTT)...
  7. ncbi Selective loss of spinal GABAergic or glycinergic neurons is not necessary for development of thermal hyperalgesia in the chronic constriction injury model of neuropathic pain
    E Polgar
    Spinal Cord Group, Institute of Biomedical and Life Sciences, West Medical Building, University of Glasgow, Glasgow G12 8QQ, UK
    Pain 104:229-39. 2003
    ..Our results suggest that significant loss of GABAergic or glycinergic neurons is not necessary for the development of thermal hyperalgesia in the CCI model of neuropathic pain...
  8. ncbi Beyond neurons: evidence that immune and glial cells contribute to pathological pain states
    Linda R Watkins
    Department of Psychology and the Center for Neuroscience, University of Colorado at Boulder, Boulder, Colorado
    Physiol Rev 82:981-1011. 2002
    ..Indeed, all nerves and neurons regardless of modality or function are likely affected by immune and glial activation in the ways described for pain...
  9. pmc Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: evidence for mitochondrial dysfunction
    Sarah J L Flatters
    Anaesthesia Research Unit, McGill University, Montreal, Que, Canada
    Pain 122:245-57. 2006
    ..Instead, our data suggest that a paclitaxel-induced abnormality in axonal mitochondria of sensory nerves contributes to paclitaxel-induced pain...
  10. ncbi Increased prevalence of impaired glucose tolerance in patients with painful sensory neuropathy
    J R Singleton
    Division of Neuromuscular Disease, Department of Neurology, University of Utah, Salt Lake City, Utah 84132, USA
    Diabetes Care 24:1448-53. 2001
    ....
  11. ncbi Chemotherapy-induced peripheral neuropathy: prevention and treatment
    D R Pachman
    Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Clin Pharmacol Ther 90:377-87. 2011
    ..Finally, there is a lack of evidence of effective treatments for the paclitaxel acute pain syndrome (P-APS), which appears to be caused by neurologic injury...
  12. ncbi Peripheral neuropathy induced by microtubule-stabilizing agents
    James J Lee
    Breast Cancer Section, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20889 5015, USA
    J Clin Oncol 24:1633-42. 2006
    ....
  13. pmc Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER Study
    Ronald J Ellis
    HIV Neurobehavioral Research Center, Department of Neurosciences, University of California, San Diego, San Diego, CA 92103, USA
    Arch Neurol 67:552-8. 2010
    ..To provide updated estimates of the prevalence and clinical impact of human immunodeficiency virus-associated sensory neuropathy (HIV-SN) and neuropathic pain due to HIV-SN in the combination antiretroviral therapy (CART) era...
  14. ncbi Chemotherapy-induced peripheral neuropathy
    Stefan Quasthoff
    Department of Neurology, Karl Franzens Universitat Graz, Austria
    J Neurol 249:9-17. 2002
    ..The recovery from symptoms is often incomplete and a long period of regeneration is required to restore function. Up to now, no drug is available to reliably prevent or cure chemotherapy-induced neuropathy...
  15. ncbi Prevalence of lower-extremity disease in the US adult population >=40 years of age with and without diabetes: 1999-2000 national health and nutrition examination survey
    Edward W Gregg
    Division of Diabetes Translation, Centers for Disease Control and Prevention, Centers for Diseases Control and Prevention, Atlanta, GA 30341, USA
    Diabetes Care 27:1591-7. 2004
    ..The aim of this study was to examine the prevalence of lower-extremity PAD, PN, and overall LED in the overall U.S. population and among those with and without diagnosed diabetes...
  16. ncbi The extracellular matrix affects axonal regeneration in peripheral neuropathies
    S C Previtali
    Department of Neurology and INSPE, Neuropathology Unit, San Raffaele Scientific Institute, Via Olgettina 60, 20132 Milano, Italy
    Neurology 71:322-31. 2008
    ..Recent evidence in animal models suggests that components of the extracellular matrix (ECM) play a primary role in peripheral nerve degeneration and regeneration...
  17. ncbi Characterization of chronic constriction of the saphenous nerve, a model of neuropathic pain in mice showing rapid molecular and electrophysiological changes
    Jean Sébastien Walczak
    Department of Pharmacology, Universite de Montreal, Montreal, Quebec, Canada
    J Neurosci Res 83:1310-22. 2006
    ..This model takes advantage of the possible use in the future of genetically modified mice and of an exclusively sensory nerve for a comprehensive study of peripheral mechanisms of neuropathic pain...
  18. ncbi Underdiagnosis of peripheral neuropathy in type 2 diabetes
    William H Herman
    Department of Internal Medicine and Epidemiology, University of Michigan Health System, 1500 East Medical Center Drive, 3920 Taubman Center, Ann Arbor, MI 48109 0354, USA
    Diabetes Care 28:1480-1. 2005
  19. ncbi Animal models of chemotherapy-evoked painful peripheral neuropathies
    Nicolas Authier
    UMR INSERM 766, Clermont Ferrand F 63001, France
    Neurotherapeutics 6:620-9. 2009
    ..In a second part, data available on neuroprotectants and treatment strategies, evaluated using these previous animal models in the attempt to prevent neuropathic pain, will be summarized...
  20. pmc Cannabinoid type-1 receptor reduces pain and neurotoxicity produced by chemotherapy
    Iryna A Khasabova
    Department of Diagnostic and Biological Sciences, University of Minnesota, Minneapolis, Minnesota 55455, USA
    J Neurosci 32:7091-101. 2012
    ..Collectively, these results suggest that pharmacological facilitation of AEA signaling is a promising strategy for attenuating cisplatin-associated sensory neuropathy...
  21. ncbi Cannabinoid agonist WIN 55,212-2 prevents the development of paclitaxel-induced peripheral neuropathy in rats. Possible involvement of spinal glial cells
    Elisa Burgos
    Department of Pharmacology and Nutrition, Faculty of Health Sciences, Rey Juan Carlos University, 28922 Alcorcon, Madrid, Spain
    Eur J Pharmacol 682:62-72. 2012
    ....
  22. ncbi The utility of skin biopsy for prediction of progression in suspected small fiber neuropathy
    C H Gibbons
    Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Neurology 66:256-8. 2006
    ..Patients without nerve fiber swellings did not have changes in nerve fiber density between biopsies. Patients with large nerve fiber swellings were most likely to present clinically with paresthesias (p < 0.05)...
  23. pmc Myofibrillar myopathies
    Duygu Selcen
    Department of Neurology, Division of Child Neurology and Neuromuscular Disease Research Laboratory, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, MN, USA
    Neuromuscul Disord 21:161-71. 2011
    ..However, in the majority of the myofibrillar myopathy patients the disease gene awaits discovery...
  24. ncbi Intravenous paclitaxel administration in the rat induces a peripheral sensory neuropathy characterized by macrophage infiltration and injury to sensory neurons and their supporting cells
    Christopher M Peters
    Departments of Diagnostic and Biological Sciences, Neuroscience, Psychiatry, Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA
    Exp Neurol 203:42-54. 2007
    ..An understanding of the factors involved in the development and maintenance of PN may lead to mechanism based therapies that prevent/treat PN and thus improve the survival and quality of life of patients receiving chemotherapy...
  25. ncbi Neurological manifestations of primary Sjogren's syndrome
    Josiah Chai
    Department of Neurology, National Neuroscience Institute, Singapore
    Curr Opin Neurol 23:509-13. 2010
    ..This review summarizes our current understanding of the neurological manifestations of primary Sjogren's syndrome (PSS), their pathophysiology, and treatment...
  26. ncbi Mitochondrial haplogroups and peripheral neuropathy during antiretroviral therapy: an adult AIDS clinical trials group study
    Todd Hulgan
    Division of Infectious Diseases, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37203, USA
    AIDS 19:1341-9. 2005
    ..The objective of this study was to determine if NRTI-associated peripheral neuropathy is associated with European mitochondrial haplogroups...
  27. pmc Neuropathic pain: a practical guide for the clinician
    Ian Gilron
    Department of Anesthesiology, Queen s University and Kingston General Hospital, Kingston, Ont
    CMAJ 175:265-75. 2006
    ..In coming years, several advances are expected in the basic and clinical sciences of neuropathic pain, which will provide new and improved therapies for patients who continue to experience this disabling condition...
  28. ncbi Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial
    D I Abrams
    Community Consortium, Positive Health Program, San Francisco General Hospital, San Francisco, CA 94110, USA
    Neurology 68:515-21. 2007
    ..To determine the effect of smoked cannabis on the neuropathic pain of HIV-associated sensory neuropathy and an experimental pain model...
  29. ncbi Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy
    Andrea Pace
    Neuroscience Department, Experimental Chemotherapy Laboratory, Regina Elena National Cancer Institute, Rome, Italy
    J Clin Oncol 21:927-31. 2003
    ..The aim of this study is to evaluate the neuroprotective effect of antioxidant supplementation with vitamin E in patients treated with cisplatin chemotherapy...
  30. ncbi Evaluation of acupuncture in the management of chemotherapy-induced peripheral neuropathy
    Graeme K Donald
    Complementary Therapy Service, the Christie NHS Foundation Trust, Wilmslow Road, Manchester M20 4BX, UK
    Acupunct Med 29:230-3. 2011
    ..To clinically evaluate the effectiveness of acupuncture when used in the management of chemotherapy-induced peripheral neuropathy (PN)...
  31. pmc Mitochondrial abnormality in sensory, but not motor, axons in paclitaxel-evoked painful peripheral neuropathy in the rat
    W H Xiao
    Department of Anesthesia, McGill University, Montreal, QC, Canada
    Neuroscience 199:461-9. 2011
    ....
  32. ncbi Human immunodeficiency virus-associated peripheral neuropathies
    Sergio Ferrari
    Department of Neurological and Visual Sciences, Section of Neurology, University of Verona, Verona, Italy
    Mayo Clin Proc 81:213-9. 2006
    ....
  33. ncbi The effect of corticosteroids usage on bacterial killing, clearance and nerve damage in leprosy; part 3--Study of two comparable groups of 100 multibacillary (MB) patients each, treated with MDT + steroids vs. MDT alone, assessed at 6 months post-release
    Vanaja Prabhakar Shetty
    The Foundation for Medical Research, 84 A, R G Thadani Marg, Worli, Mumbai 400 018, India
    Lepr Rev 81:41-58. 2010
    ..To investigate effects of therapeutic usage of corticosteroids on M. leprae killing and clearance, on clearance of granuloma and on nerve damage in multibacillary (MB) leprosy patients...
  34. pmc A phase two randomised controlled double blind trial of high dose intravenous methylprednisolone and oral prednisolone versus intravenous normal saline and oral prednisolone in individuals with leprosy type 1 reactions and/or nerve function impairment
    Stephen L Walker
    Department of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom
    PLoS Negl Trop Dis 5:e1041. 2011
    ....
  35. ncbi Leprosy type 1 (reversal) reactions and their management
    Stephen L Walker
    Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, Keppel St, London WC1E 7HT, UK
    Lepr Rev 79:372-86. 2008
    ..Searches were complete to the end of November 2008...
  36. ncbi Oxaliplatin acts on IB4-positive nociceptors to induce an oxidative stress-dependent acute painful peripheral neuropathy
    Elizabeth K Joseph
    Department of Medicine, Division of Neuroscience, University of California, San Francisco, San Francisco, California 94143 0440, USA
    J Pain 9:463-72. 2008
    ..We suggest that oxaliplatin acts on IB4 (+)-nociceptors to induce oxidative stress-dependent acute peripheral sensory neuropathy...
  37. ncbi Inhibition of neuropathic pain by decreased expression of the tetrodotoxin-resistant sodium channel, NaV1.8
    Josephine Lai
    Department of Pharmacology, University of Arizona Health Sciences Center, Tucson, AZ 85724, USA
    Pain 95:143-52. 2002
    ..These data provide direct evidence linking NaV1.8 to neuropathic pain. As NaV1.8 expression is restricted to sensory neurons, this channel offers a highly specific and effective molecular target for the treatment of neuropathic pain...
  38. ncbi Hemochromatosis (HFE) gene mutations and peripheral neuropathy during antiretroviral therapy
    Asha R Kallianpur
    Department of Medicine, Divisions of General Internal Medicine and Public Health, Nashville, TN, USA
    AIDS 20:1503-13. 2006
    ..Since iron deficiency is associated with some types of PN, and iron is essential for mitochondrial function, we tested the hypothesis that hemochromatosis (HFE) gene mutations influence susceptibility to NRTI-induced PN...
  39. ncbi Simple screening tests for peripheral neuropathy in the diabetes clinic
    B A Perkins
    Beth Israel Deaconness Medical Center and Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts, USA
    Diabetes Care 24:250-6. 2001
    ..The reported operating characteristics for each sensory modality can be applied to positive findings on the physical examination of individual patients to predict the likelihood of neuropathy...
  40. pmc Altered C-fiber function as an indicator of early peripheral neuropathy in individuals with impaired glucose tolerance
    Alistair Q Green
    The Diabetes Research Centre, Ipswich Hospital National Health Service Trust, Suffolk, UK
    Diabetes Care 33:174-6. 2010
    ....
  41. ncbi Alpha-lipoic acid prevents mitochondrial damage and neurotoxicity in experimental chemotherapy neuropathy
    Giorgia Melli
    Neuromuscular Diseases Unit, IRCCS Foundation Neurological Institute Carlo Besta, Via Celoria, 11 20133, Milan, Italy
    Exp Neurol 214:276-84. 2008
    ..These findings suggest that alpha-lipoic acid might reduce the risk of developing peripheral nerve toxicity in patients undergoing chemotherapy and encourage further confirmatory clinical trials...
  42. ncbi Recent findings on how proinflammatory cytokines cause pain: peripheral mechanisms in inflammatory and neuropathic hyperalgesia
    Claudia Sommer
    Department of Neurology, University of Wurzburg, Josef Schneider Strasse 11, D 97080 Wurzburg, Germany
    Neurosci Lett 361:184-7. 2004
    ..Here we summarize recent findings on the peripheral mechanisms of action of three prototypic proinflammatory cytokines, interleukin-1beta, interleukin-6 and tumor necrosis factor-alpha, with regards to pain and hyperalgesia...
  43. ncbi A painful peripheral neuropathy in the rat produced by the chemotherapeutic drug, paclitaxel
    R C Polomano
    Department of Anesthesiology, Milton S Hershey Medical Center, The Pennsylvania State University College of Medicine, Hershey, PA 17033, USA
    Pain 94:293-304. 2001
    ..This model may be useful in understanding a significant source of pain in cancer patients, and in finding ways to avoid the neurotoxicity that limits paclitaxel therapy...
  44. ncbi Retrograde signaling in axonal regeneration
    Ida Rishal
    Department of Biological Chemistry, Weizmann Institute of Science, 76100 Rehovot, Israel
    Exp Neurol 223:5-10. 2010
    ..Encouraging recent data suggest that it may be possible to apply this emerging understanding of retrograde signaling mechanisms to activate intrinsic regeneration mechanisms also in growth-refractory central neurons...
  45. pmc "Listening" and "talking" to neurons: implications of immune activation for pain control and increasing the efficacy of opioids
    Linda R Watkins
    Department of Psychology and Center for Neuroscience, University of Colorado at Boulder, Boulder, CO 80309 0345, USA
    Brain Res Rev 56:148-69. 2007
    ..Such changes in neuronal function would be expected to occur wherever immune-derived substances come in close contact with neurons...
  46. ncbi Experimental and clinical applications of quantitative sensory testing applied to skin, muscles and viscera
    Lars Arendt-Nielsen
    Department of Health Sciences and Technology, Center for Sensory Motor Interaction, Aalborg University, Aalborg, Denmark
    J Pain 10:556-72. 2009
    ..Assessing pain has become a question of solving a multi-input, multi-output problem, with the solution providing the possibility of teasing out which pain pathways and mechanisms are involved, impaired, or affected...
  47. ncbi Inhibition of paclitaxel-induced A-fiber hypersensitization by gabapentin
    Misaki Matsumoto
    Division of Molecular Pharmacology and Neuroscience, Nagasaki University Graduate School of Biomedical Sciences, 1 14 Bunkyo machi, Nagasaki 852 8521, Japan
    J Pharmacol Exp Ther 318:735-40. 2006
    ....
  48. ncbi Impaired glucose tolerance and neuropathy
    A Gordon Smith
    Department of Neurology, University of Utah, Salt Lake City, Utah 84132, USA
    Neurologist 14:23-9. 2008
    ..Among this population, impaired glucose tolerance (IGT or "prediabetes") is observed in approximately 40%. The exact nature of the relationship between IGT and neuropathy is debated...
  49. pmc Paclitaxel- and vincristine-evoked painful peripheral neuropathies: loss of epidermal innervation and activation of Langerhans cells
    Chiang Siau
    Department of Anesthesia, McGill University, Montreal, Quebec, Canada
    Exp Neurol 201:507-14. 2006
    ..Partial degeneration of the intraepidermal innervation suggests mechanisms that might produce chemotherapy-evoked neuropathic pain, and activation of cutaneous LCs suggests possible neuroimmune interactions that might also have a role...
  50. ncbi Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat
    Guido Cavaletti
    Department of Neurosciences and Biomedical Technologies, University of Milan Bicocca, Monza, Italy
    Exp Neurol 204:317-25. 2007
    ..This model is relevant to the neuropathy induced by bortezomib in the treatment of human malignancies and it could be useful in increasing our knowledge regarding the mechanisms underlying bortezomib neurotoxicity...
  51. ncbi Glutamate carboxypeptidase inhibition reduces the severity of chemotherapy-induced peripheral neurotoxicity in rat
    Valentina A Carozzi
    Department of Neurosciences and Biomedical Technologies, University of Milano Bicocca, U8, Via Cadore 48, 20052 Monza MB, Italy
    Neurotox Res 17:380-91. 2010
    ..Our data support a novel approach for the treatment of chemotherapy-induced peripheral neuropathy...
  52. ncbi Central pain in multiple sclerosis--prevalence and clinical characteristics
    A Osterberg
    Department of Neuroscience and Locomotion, Division of Neurology, University Hospital, Linkoping, Sweden
    Eur J Pain 9:531-42. 2005
    ..Both types of CP existed either chronically or as a feature of relapse. Central pain is thus an important symptom in MS (around 30%) and causes much suffering...
  53. ncbi Spontaneous action potential activity in isolated dorsal root ganglion neurons from rats with a painful neuropathy
    R E Study
    Dept of Anesthesia, Brigham and Women s Hospital Boston, MA 02115, USA
    Pain 65:235-42. 1996
    ....
  54. ncbi Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine
    Javier Cortes
    Vall d Hebron University Hospital, Barcelona, Spain
    J Clin Oncol 28:3922-8. 2010
    ....
  55. pmc A rapamycin-sensitive signaling pathway is essential for the full expression of persistent pain states
    Sandrine M Géranton
    Department of Cell and Developmental Biology, University College London, London WC1E 6BT, United Kingdom
    J Neurosci 29:15017-27. 2009
    ....
  56. ncbi Immunocytochemical localization of P2X3 purinoceptors in sensory neurons in naive rats and following neuropathic injury
    S D Novakovic
    Center for Biological Research, Roche Bioscience, Palo Alto, CA 94304 1397, USA
    Pain 80:273-82. 1999
    ..In addition, the spinal cord immunoreactivity increased in magnitude on the side ipsilateral to the ligated nerve, consistent with up-regulation of receptors in presynaptic terminals of the primary sensory neurons...
  57. ncbi Corticosteroids for treating nerve damage in leprosy. A Cochrane review
    Natasja H J Van Veen
    Department of Public Health, Erasmus MC, University Medical Center Rotterdam, The Netherlands
    Lepr Rev 79:361-71. 2008
    ..Corticosteroids are commonly used for treating nerve damage in leprosy. We assessed the effectiveness of corticosteroids for treating nerve damage due to leprosy...
  58. ncbi [Clinical randomized controlled study on acupuncture for treatment of peripheral neuropathy induced by chemotherapeutic drugs]
    Wei Ru Xu
    Beijing University of CM, Beijing 100029, China
    Zhongguo Zhen Jiu 30:457-60. 2010
    ..To seek the effective treatment for peripheral neuropathy induced by chemotherapeutic drugs...
  59. pmc CNS-infiltrating CD4+ T lymphocytes contribute to murine spinal nerve transection-induced neuropathic pain
    Ling Cao
    Department of Anesthesiology, Dartmouth Hitchcock Medical Center, Lebanon, NH 03756, USA
    Eur J Immunol 38:448-58. 2008
    ..These results strongly support a contributing role of spinal cord-infiltrating CD4(+) T lymphocytes versus peripheral CD4(+) T lymphocytes in the maintenance of nerve injury-induced neuropathic pain...
  60. pmc Transient Receptor Potential Vanilloid 1 is essential for cisplatin-induced heat hyperalgesia in mice
    Lauren E Ta
    Program in Molecular Neuroscience, Mayo Graduate School, Mayo Clinic, College of Medicine, Rochester, MN 55905, USA
    Mol Pain 6:15. 2010
    ..The mechanisms underlying painful platinum-induced neuropathy remain poorly understood. Previous studies have demonstrated important roles for TRPV1, TRPM8, and TRPA1 in inflammation and nerve injury induced pain...
  61. ncbi High activity and reduced neurotoxicity of bi-fractionated oxaliplatin plus 5-fluorouracil/leucovorin for elderly patients with advanced colorectal cancer
    R Mattioli
    S Croce Hospital, Medical Oncology Unit, Fano
    Ann Oncol 16:1147-51. 2005
    ..The proportion of elderly within the general population is increasing and the incidence of colorectal cancer increases with age. Oxaliplatin and 5-fluorouracil (FU) combination is active in this disease...
  62. ncbi Evaluation of peripheral and autonomic neuropathy among patients with newly diagnosed impaired glucose tolerance
    Baris Isak
    Marmara University, Department of Neurology, Istanbul, Turkey
    Diabetes Metab Res Rev 24:563-9. 2008
    ....
  63. pmc Behavioral and electrophysiological studies in rats with cisplatin-induced chemoneuropathy
    Juan P Cata
    The Department of Anesthesiology and Pain Medicine, The University of Texas M D Anderson Cancer Center 1400 Holcombe Blvd, Unit 409 Houston, TX 77030, USA
    Brain Res 1230:91-8. 2008
    ....
  64. pmc Sensory nerve excitability and neuropathy in end stage kidney disease
    A V Krishnan
    Prince of Wales Medical Research Institute, University of New South Wales, Sydney, NSW 2031, Australia
    J Neurol Neurosurg Psychiatry 77:548-51. 2006
    ..Peripheral neuropathy is present in 65% of patients with end stage kidney disease (ESKD) starting dialysis. Studies of membrane potential and axonal ion channel function may help explain the pathophysiology...
  65. ncbi Caspase signalling in neuropathic and inflammatory pain in the rat
    Elizabeth K Joseph
    Department of Medicine, Division of Neuroscience and Biomedical Sciences Programme, NIH Pain Centre, Box 0440 C522, University of California, San Francisco, San Francisco, CA 94143, USA
    Eur J Neurosci 20:2896-902. 2004
    ..This suggests that these pathways are potential targets for novel pharmacological agents for the treatment of inflammatory as well as neuropathic pain...
  66. pmc Intrathecal interleukin-10 gene therapy attenuates paclitaxel-induced mechanical allodynia and proinflammatory cytokine expression in dorsal root ganglia in rats
    Annemarie Ledeboer
    Department of Psychology and the Center for Neuroscience, University of Colorado at Boulder, Boulder, CO, USA
    Brain Behav Immun 21:686-98. 2007
    ..We propose that targeting the production of proinflammatory cytokines by intrathecal IL-10 gene therapy may be a promising therapeutic strategy for the relief of paclitaxel-induced neuropathic pain...
  67. ncbi HIV neuropathy risk factors and symptom characterization in stavudine-exposed South Africans
    Antonia L Wadley
    Brain Function Research Group, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
    J Pain Symptom Manage 41:700-6. 2011
    ..HIV-associated sensory neuropathy (HIV-SN) is a frequent complication of both HIV and neurotoxic antiretroviral medications such as stavudine...
  68. ncbi Post-surgical inflammatory neuropathy
    Nathan P Staff
    Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Brain 133:2866-80. 2010
    ..In 13 cases with longitudinal follow-up (median 9 months, range 3-71 months), the median neuropathy impairment score improved from 30 to 24 at the time of last evaluation (P=0.001)...
  69. ncbi Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy
    T J Lehky
    Department of Neurology, National Naval Medical Center, 8901 Wisconsin Avenue, Bethesda, MD 20889, USA
    Muscle Nerve 29:387-92. 2004
    ..Chronic treatment causes an axonal neuropathy similar to other platinum-based chemotherapeutic agents...
  70. ncbi Mice overexpressing chemokine ligand 2 (CCL2) in astrocytes display enhanced nociceptive responses
    J Menetski
    Department of Immunology and Rheumatology, Merck Research Laboratories, P O Box 2000, Rahway, NJ 07065, USA
    Neuroscience 149:706-14. 2007
    ..Taken together with data from CCR2-deficient mice, these present data confirm a key role of CCL2/CCR2 axis in pain pathways and suggest that inhibiting this axis may result in novel pain therapies...
  71. ncbi Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3)
    Ravi D Rao
    Department of Medical Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Cancer 110:2110-8. 2007
    ..On the basis of these data, a multicenter, double-blind, placebo-controlled, crossover, randomized trial was conducted to evaluate the effect of gabapentin on symptoms of chemotherapy-induced peripheral neuropathy (CIPN)...
  72. ncbi Peripheral neuropathies in Sjögren's syndrome: a critical update on clinical features and pathogenetic mechanisms
    P P Pavlakis
    Neuroimmunology Unit, Department of Pathophysiology, Faculty of Medicine, National and Kapodistrian University of Athens, 75 Mikras Asias Str, Athens 11527, Greece
    J Autoimmun 39:27-33. 2012
    ..In this review, the frequency, prevalence and diagnostic criteria for each neuropathy subset are discussed and possible pathogenetic mechanisms are outlined...
  73. pmc The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase III clinical trial
    Lisa A Kottschade
    Mayo Clinic, Rochester, MN 55905, USA
    Support Care Cancer 19:1769-77. 2011
    ..Chemotherapy-induced peripheral neuropathy (CIPN) continues to be a substantial problem for many cancer patients. Pursuant to promising appearing pilot data, the current study evaluated the use of vitamin E for the prevention of CIPN...
  74. ncbi Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial
    Annemiek Broyl
    Department of Haematology, Erasmus MC, Rotterdam, Netherlands
    Lancet Oncol 11:1057-65. 2010
    ....
  75. ncbi Contribution of degeneration of motor and sensory fibers to pain behavior and the changes in neurotrophic factors in rat dorsal root ganglion
    Koichi Obata
    Department of Anatomy and Neuroscience, Hyogo College of Medicine, Nishinomiya, Hyogo 663 8501, Japan
    Exp Neurol 188:149-60. 2004
    ..The ventral rhizotomy and ganglionectomy models may be useful to investigate the pathophysiological mechanisms of neuropathic pain after Wallerian degeneration in motor or sensory or mixed nerve...
  76. ncbi HIV neuropathy in South Africans: frequency, characteristics, and risk factors
    Jean Maritz
    Division of Neurology, Department of Medicine, University of Cape Town, Observatory 7925, Cape Town, South Africa
    Muscle Nerve 41:599-606. 2010
    ..Our findings raise the possibility that the incidence of DSP may be reduced with avoidance of stavudine-containing regimens in older subjects, especially with a history of prior TB infection...
  77. ncbi HIV-associated sensory neuropathy: risk factors and genetics
    Peter R Kamerman
    Brain Function Research Group, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, 7 York Road, Parktown, South Africa
    Curr Pain Headache Rep 16:226-36. 2012
    ..Thus, more work is required to identify the principal factors that increase an individual's risk for HIV-SN so that effective preventative or therapeutic strategies can be implemented...
  78. ncbi Enhancement of axonal potassium conductance reduces nerve hyperexcitability in an in vitro model of oxaliplatin-induced acute neuropathy
    Ruth Sittl
    Institute of Physiology, Ludwig Maximilians University, Pettenkoferstr 12, Munich, Germany
    Neurotoxicology 31:694-700. 2010
    ..The data indicate that activation of slow potassium channels in the A-fibres of peripheral nerve may attenuate the acute neuropathy associated with oxaliplatin in humans...
  79. ncbi Mexiletine reverses oxaliplatin-induced neuropathic pain in rats
    Nobuaki Egashira
    Department of Pharmacy, Kyushu University Hospital, Japan
    J Pharmacol Sci 112:473-6. 2010
    ..p., twice a week). Lidocaine (30, but not 3 and 10, mg/kg, i.p.) also significantly relieved both pain behaviors. These results suggest that mexiletine may be effective in relieving the oxaliplatin-induced neuropathic pain clinically...
  80. ncbi Satellite glial cells in sensory ganglia: from form to function
    Menachem Hanani
    Laboratory of Experimental Surgery, Hadassah University Hospital, Mount Scopus, Jerusalem 91240, Israel
    Brain Res Brain Res Rev 48:457-76. 2005
    ..Damage to the axons of sensory ganglia is known to contribute to neuropathic pain. Such damage also affects SGCs, and it can be proposed that these cells have a role in pathological changes in the ganglia...
  81. ncbi Neurofibromatosis 1-associated neuropathies: a reappraisal
    Alain Drouet
    Service de Neurologie, Hopital d Instruction des Armees Desgenettes, Lyon, France
    Brain 127:1993-2009. 2004
    ..Association of proximal large neurofibromas, peripheral neuropathies and subcutaneous neurofibromas may constitute a phenotype of NF1 with a severe prognosis...
  82. ncbi Chemotherapy-induced peripheral neurotoxicity
    Guido Cavaletti
    Department of Neuroscience and Biomedical Technologies, University of Milano Bicocca, Via Cadore 48, Monza, Italy
    Nat Rev Neurol 6:657-66. 2010
    ....
  83. ncbi Orally active neurotrophin-enhancing agent protects against dysfunctions of the peripheral nerves in hyperglycemic animals
    Bunpei Kakinoki
    Research Laboratory I, Pharmaceutical Research Unit, Research and Development Division, Mitsubishi Pharma Corporation, 1000, Kamoshida cho, Aoba ku, Yokohama 227 0033, Japan
    Diabetes 55:616-21. 2006
    ..Thus, the orally active neurotrophin enhancer provides a new option for the clinical treatment of diabetic peripheral neuropathy...
  84. ncbi Altered motor nerve excitability in end-stage kidney disease
    Arun V Krishnan
    Institute of Neurological Sciences, Prince of Wales Hospital, Randwick, Sydney, Australia
    Brain 128:2164-74. 2005
    ..The correlation between serum K+ and excitability measures indicates that hyperkalaemia is primarily responsible for uraemic depolarization, and a likely contributing factor to the development of neuropathy...
  85. ncbi Efficacy of rituximab in primary Sjogren's syndrome with peripheral nervous system involvement: results from the AIR registry
    A Mekinian
    Department of Internal Medicine, Hopital Jean Verdier, Assistance Publique Hopitaux de Paris, Université Paris Sud 13, Bondy, France
    Ann Rheum Dis 71:84-7. 2012
    ..To evaluate rituximab (RTX) in primary Sjögren's syndrome (pSS) with peripheral nervous system (PNS) involvement...
  86. ncbi Pain in oxaliplatin-induced neuropathy--sensitisation in the peripheral and central nociceptive system
    Andreas Binder
    Division of Neurological Pain Research and Therapy, Christian Albrechts Universitat Kiel, Schittenhelmstrasse 10, 24105 Kiel, Germany
    Eur J Cancer 43:2658-63. 2007
    ..This study aimed to determine the somatosensory characteristics and pain types in patients with acute oxaliplatin-induced neuropathy and to relate this profile to the hereby detected underlying pathophysiological mechanisms...
  87. ncbi A review on oxaliplatin-induced peripheral nerve damage
    Andreas A Argyriou
    Department of Neurology, EMG Laboratory, University of Patras Medical School, Rion Patras, Greece
    Cancer Treat Rev 34:368-77. 2008
    ..However, the clinical data are still controversial. We herein review and discuss the pathogenesis, incidence, risk factors, diagnosis, characteristics and management of OXLIPN. We also highlight areas of future research...
  88. ncbi Initiation of antiretroviral therapy at CD4 cell counts >/=350 cells/mm3 does not increase incidence or risk of peripheral neuropathy, anemia, or renal insufficiency
    Kenneth A Lichtenstein
    University of Colorado Health Sciences Center, Denver, CO, USA
    J Acquir Immune Defic Syndr 47:27-35. 2008
    ..US guidelines recommend deferring initiation of highly active antiretroviral therapy (HAART) for most patients with CD4 counts >350 cells/mm in part because of concerns about antiretroviral toxicity...
  89. ncbi NGF protects dorsal root ganglion neurons from oxaliplatin by modulating JNK/Sapk and ERK1/2
    Arianna Scuteri
    Dipartimento di Neuroscienze e Tecnologie Biomediche, Universita degli Studi di Milano Bicocca, Via Cadore 48, 20052 Monza, Italy
    Neurosci Lett 486:141-5. 2010
    ..However, it is also important, as is JNK/Sapk, in preserving the correct cellular differentiation that is pivotal for neuronal survival...
  90. ncbi Clinical characteristics and pain management among patients with painful peripheral neuropathic disorders in general practice settings
    Mugdha Gore
    Avalon Health Solutions Inc, Philadelphia, PA 19102, USA
    Eur J Pain 11:652-64. 2007
    ....
  91. ncbi Acupuncture for chemotherapy-induced peripheral neuropathy (CIPN): a pilot study using neurography
    Sven Schroeder
    HanseMerkur Centre for TCM at the University Medical Center, UKE Campus, House O55, Martinistrasse 52, 20246, Hamburg, Germany
    Acupunct Med 30:4-7. 2012
    ..Specific and effective curative treatments are lacking...
  92. ncbi Role of integrins in peripheral nerves and hereditary neuropathies
    Caterina Berti
    San Raffaele Scientific Institute, DIBIT, Via Olgettina 58, 20132 Milano, Italy
    Neuromolecular Med 8:191-204. 2006
    ..Then we use information derived from recent experiments of targeted mutagenesis in mice to show that, consistent with temporally regulated expression, different integrins serve multiple roles in developing nerve...
  93. pmc Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia
    Tristan M Sissung
    Clinical Pharmacology Research Core, National Cancer Institute, 9000 Rockville Pike, Building 10, Room 5A01, Bethesda, MD 20892, USA
    Eur J Cancer 42:2893-6. 2006
    ..This pilot study suggests that paclitaxel-induced neuropathy and neutropenia might be linked to inherited variants of ABCB1 through a mechanism that is unrelated to altered plasma pharmacokinetics...
  94. ncbi Sensory neurons and their supporting cells located in the trigeminal, thoracic and lumbar ganglia differentially express markers of injury following intravenous administration of paclitaxel in the rat
    Juan Miguel Jimenez-Andrade
    Neurosystems Center, Department of Diagnostic and Biological Sciences, University of Minnesota, Minneapolis, MN 55455, United States
    Neurosci Lett 405:62-7. 2006
    ..These results provide a pathological basis for the anatomical distribution of paclitaxel-induced symptoms in patients receiving therapeutic regimens of paclitaxel...
  95. pmc Increased chemokine signaling in a model of HIV1-associated peripheral neuropathy
    Sonia K Bhangoo
    Molecular Pharmacology, Northwestern University, Chicago, IL, USA
    Mol Pain 5:48. 2009
    ....
  96. ncbi Tumor necrosis factor-alpha induces long-term potentiation of C-fiber evoked field potentials in spinal dorsal horn in rats with nerve injury: the role of NF-kappa B, JNK and p38 MAPK
    Yan Ling Liu
    Pain Research Center, Zhongshan Medical School of Sun Yat Sen University, 510089 Guangzhou, PR China
    Neuropharmacology 52:708-15. 2007
    ..These results suggest that TNF-alpha and its downstream molecules may have no acute effect on spinal synaptic transmission in intact animals and induce LTP in rats with neuropathic pain produced by nerve injury...
  97. ncbi The role of oxidative stress and anti-oxidant treatment in platinum-induced peripheral neurotoxicity
    V A Carozzi
    Department of Neurosciences and Biomedical Technologies, University of Milano Bicocca, Monza MI, Italy
    Curr Cancer Drug Targets 10:670-82. 2010
    ..In this review, an update on the current knowledge on the relationship existing between oxidative stress and platinum drugs peripheral neurotoxicity will be given...
  98. ncbi Oxaliplatin-associated neuropathy: a review
    Robert J Cersosimo
    School of Pharmacy, Northeastern University, Boston, MA 02115 5000, USA
    Ann Pharmacother 39:128-35. 2005
    ..To review the incidence, mechanism, signs, symptoms, and management of oxaliplatin-induced neurotoxicity...
  99. ncbi A randomized controlled trial evaluating the efficacy and safety of vitamin E supplementation for protection against cisplatin-induced peripheral neuropathy: final results
    Andreas A Argyriou
    EMG ENG Laboratory, Department of Neurology, University of Patras Medical School, Rion Patras, Greece
    Support Care Cancer 14:1134-40. 2006
    ..A randomized, open label with blind assessment, controlled trial was performed to assess efficacy and adverse-event profile of vitamin E, given as supplementation for prophylaxis against cisplatin-induced peripheral neuropathy (CIPN)...
  100. ncbi Activation of microglia and p38 mitogen-activated protein kinase in the dorsal column nucleus contributes to tactile allodynia following peripheral nerve injury
    R Terayama
    Department of Oral Function and Anatomy, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2 5 1 Shikata cho, Okayama, Japan
    Neuroscience 153:1245-55. 2008
    ..Activation of p38 MAPK in medullary microglia may contribute to the pathogenesis of neuropathic pain...
  101. ncbi Ganglioside GM1 (porcine) ameliorates paclitaxel-induced neuropathy in rats
    Vilai Chentanez
    Peripheral Nerve Research Unit, Department ofAnatomy, Faculty of Medicine, Chulalongkorn University, Bangkok
    J Med Assoc Thai 92:50-7. 2009
    ..Monosialic acid ganglioside (GM1) has been shown to protect neurons against injuries and degeneration. However, its efficacy in the treatment of paclitaxel-induced neuropathy has not been verified...

Research Grants74

  1. 2010 Neuropathy Physicians Conference
    TINA MARIE TOCKARSHEWSKY; Fiscal Year: 2010
    ....
  2. REHABILITATION OF MICRONEUROVASCULAR GRAFTS IN OLD RATS
    Lisa Larkin; Fiscal Year: 2000
    ..In addition, the proposed study will examine the effectiveness of chronic low frequency electrical stimulation as an intervention to enhance rehabilitation of senescent MGN muscle from a microneurovascular grafting procedure. ..
  3. PERIPHERAL NERVE INJURY AND RECOVERY OF FUNCTION
    Richard Nichols; Fiscal Year: 2004
    ..In Project 5, the manner in which abnormalities of proprioceptive pathways result in loss of coordination will be studied during locomotion and targeted reaching. ..
  4. HIV GP120 EFFECTS ON NEUROTRANSMISSION
    RICHARD ZIEGLER; Fiscal Year: 1993
    ..This information can be important for designing therapeutic compounds and strategies for treatment of "neural AIDS."..
  5. Metabolomic Signatures in ALS
    Merit Cudkowicz; Fiscal Year: 2005
    ..abstract_text> ..
  6. Diagnostic and Surrogate Markers for ALS
    LISA PAIGE; Fiscal Year: 2005
    ..Long-term goals are to use metabolomics as a powerful tool to map environmental factors that contribute to the development of neurodegnerative diseases. ..
  7. Defibrotide for the treatment of severe hepatic veno-cc*
    Paul Richardson; Fiscal Year: 2007
    ..Abstract Not Provided ..
  8. 2007 International Peripheral Nerve Society Meeting at Snowbird, Utah
    A Smith; Fiscal Year: 2007
    ..The meeting directly impacts public health and patient care by disseminating important new ideas (both research and therapeutic) and by developing consensus guidelines. [unreadable] [unreadable] [unreadable]..
  9. Peripheral neurotoxicity by the HIV-1 coat protein gp120
    Ahmet Hoke; Fiscal Year: 2007
    ..A major strength of our proposal is our use of human tissues to study a disease that only affects humans. ..
  10. PERIPHERAL NEUROPATHY, SENSORIMOTOR FUNCTIONS & BALANCE
    James Richardson; Fiscal Year: 2004
    ..Stratification of the subjects in the first group by the presence of carpal tunnel syndrome and testing the subjects in the second group at 3 and 12 weeks may give insight into the mechanisms responsible for improvement noted. ..
  11. In-Vivo Confocal Imaging of Meissner's Corpuscles as a Measure of HIV Neuropathy
    David Herrmann; Fiscal Year: 2008
    ..In-vivo RCM of MCs may prove to have wide application for early identification of sensory peripheral neuropathies, and to assess effectiveness of therapy. [unreadable] [unreadable] [unreadable]..
  12. Epidermal Innervation as an Outcome Measure
    David Herrmann; Fiscal Year: 2006
    ..Dr. Herrmann will also examine a method to simplify the analysis of skin biopsy specimens, for easier application in large clinical trials. ..
  13. Oxidant Stress and Antioxidants during HIV Therapy
    Todd Hulgan; Fiscal Year: 2007
    ..The candidate's long-term goal is to develop into an independent clinical investigator in this field of study. ..
  14. MIDCAREER INVESTIGATOR AWARD IN NEURO-AIDS RESEARCH
    David Simpson; Fiscal Year: 2005
    ..The Neuro-Adherence Program will assess the affect of neurological disease on patients' adherence to medical regimens, and the impact of education and support groups on adherence. ..
  15. Can dynamic pupillography and/or spectral analysis of heart rate variability prov
    Solomon Tesfaye; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  16. HYPOGLYCEMIA AND AUTONOMIC NERVOUS SYSTEM FUNCTION
    Roy Freeman; Fiscal Year: 2007
    ..Thus, the broad long term objectives of the proposal are to fully understand the mechanisms and consequences of hypoglycemia associated autonomic failure with the ultimate goal of finding an efficacious treatment. ..
  17. The Electrophysiology of Motor Neuron Diseases
    Mark Bromberg; Fiscal Year: 2002
    ..Currently, most MUNE techniques rely on proprietary software. We will develop software for use on PC-based computer systems, making them available to all laboratories. ..
  18. Mitochondrial Genomics and Peripheral Neuropathy during HIV Therapy
    Todd Hulgan; Fiscal Year: 2008
    ..Results from this study will also advance the field of "mitochondrial medicine", having broad application across other scientific disciplines and for other human diseases. [unreadable] [unreadable] [unreadable]..
  19. HIV Clade on Cognitive and Neurological Disorders Brazil
    Ronald Ellis; Fiscal Year: 2007
    ..UCSD investigators will train and guide the administration and interpretation of the clinical assessment instruments, transfer technology to the Brazilian site. [unreadable] [unreadable]..
  20. Nornicotine for Treatment of Pain
    JOSEPH HOLTMAN; Fiscal Year: 2007
    ..This research project focuses on the development of a novel analgesic agent, nornicotine, for pain management. [unreadable] [unreadable] [unreadable]..
  21. HIV-sensory neuropathies:risk factors, immunopathology
    Justin McArthur; Fiscal Year: 2006
    ..We will extend our studies of the immunopathology of HIV-SN, using our extensive tissue collections to define the relationship of chemokine upregulation to neuropathic pain. ..
  22. Endoplasmic Reticulum Calcium Pools in Neuropathic Pain
    LAUREN TA; Fiscal Year: 2007
    ..3): To determine whether thapsigargin, an ER calcium pump inhibitor, can reverse nerve injury-induced neuropathic pain. ..
  23. Predicting progression of NeuroAIDS
    Justin McArthur; Fiscal Year: 2007
    ..Abstract Not Provided: ..
  24. Characterizing temporal dynamics of spontaneous pain
    APKAR APKARIAN; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  25. Iron as a Nutritional Modifier of Toxic Neuropathy in HIV/AIDS
    Asha Kallianpur; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  26. Norketamine for Treatment of Pain
    JOSEPH HOLTMAN; Fiscal Year: 2008
    ..abstract_text> ..
  27. Antioxidant Gene Therapy to Treat Diabetic Neuropathy
    James Goss; Fiscal Year: 2009
    ..We will test this idea in diabetic mice, if successful; this research could lead to a possible treatment for diabetic neuropathy in humans. ..
  28. MECHANISMS OF NEURONAL DEATH AND NEUROPROTECTION
    ANTHONY JOHN WINDEBANK; Fiscal Year: 2010
    ..The goal is to develop a mechanism-based therapy that will prevent the major dose-limiting side effect of the platinum compounds. ..
  29. HIV Neurocognitive Disorders: A Randomized Clinical Trial of CNS-Targeted HAART
    Ronald J Ellis; Fiscal Year: 2010
    ..The proposed clinical trial would provide the level of evidence needed to formulate ART guidelines specific to HNCI. ..
  30. Implementation of Asthma Guidelines in Primary Care; Comparison of 4 approaches
    James W Mold; Fiscal Year: 2010
    ..If effective, the same strategies could be used to facilitate implementation of other chronic disease guidelines. ..
  31. TrkB.T1 as a Genetic Disease Modifier of Muscular Dystrophy
    CHRISTOPHER WILLIAM WARD; Fiscal Year: 2010
    ..This study will try to figure out why these two molecules may be possible therapeutic targets. Our goal is to prevent, improve, or restore muscle function in patients with muscular dystrophy. ..
  32. Biodegradable Polymer Implants for Spinal Cord Repair
    Anthony Windebank; Fiscal Year: 2006
    ..Imaging with Micro-CT and MR microscopy will be combined with histological and functional assessments to measure success in promoting regeneration. ..
  33. Osteoporosis Prevention in Early Stage Breast Cancer
    Dawn Hershman; Fiscal Year: 2006
    ..abstract_text> ..
  34. Neurite density in skin as a marker for neuropathic pain
    Anne Louise Oaklander; Fiscal Year: 2005
    ..abstract_text> ..
  35. PROSAPOSIN AND PROSAPTIDES IN DIABETIC NEUROPATHY
    NIGEL CALCUTT; Fiscal Year: 2002
    ..The goal is to establish prosaptides as novel therapeutic agents for treating diabetic neuropathy and to provide mechanistic explanations for why hyperglycemia causes nerve disorders. ..
  36. Cortical Dynamics for Pain Perception in Behaving Rats
    APKAR APKARIAN; Fiscal Year: 2005
    ..abstract_text> ..
  37. Epo-dependent JAK2 Signaling in Painful Neuropathy
    WENDY CAMPANA; Fiscal Year: 2006
    ..The experiments will provide new information on the basic mechanisms of nerve injury and pain, and there from, new rationale for development of novel neuroprotective strategies for preventing chronic neuropathic pain. ..
  38. Effects of Acupuncture on Bone Cancer Pain in Mice
    Ruixin Zhang; Fiscal Year: 2004
    ..These studies will set a stage for further studying the mechanisms of EA in the control and management of cancer pain. ..
  39. Near Infra Red Energy To Treat Diabetic Neuropathy
    NIGEL CALCUTT; Fiscal Year: 2006
    ..abstract_text> ..
  40. Selegiline, Oxidative Stress and MRS in HIV Dementia
    Giovanni Schifitto; Fiscal Year: 2003
    ..The proposed study will take advantage of the ACTG supporting A5090 study and of the existing MRS consortium infrastructure that will allow us to perform multicenter MRS studies. ..
  41. CYTOKINE-TO-BRAIN COMMUNICATION--ROLE OF THE VAGUS
    Linda Watkins; Fiscal Year: 2002
    ..Additionally, the released time will foster further professional growth by yielding coherent blocks of time for concentrating on research and review projects. ..
  42. Acupuncture for Chronic Nausea in Pts with HIV: A RCT
    JOYCE ANASTASI; Fiscal Year: 2008
    ..Pilot study results and data analytic objectives indicate the need for 53 subjects per group to ensure 80% power < 1% Type I error rate, and 16% attrition, 20% placebo effect. ..
  43. Gene Polymorphism & Treatment-Symptoms in Lung Cancer
    Cielito Reyes Gibby; Fiscal Year: 2008
    ..abstract_text> ..
  44. CYCLOOXYGENASE AND ANTI-INFLAMMATORY DRUGS IN AD
    Giulio Pasinetti; Fiscal Year: 2001
    ..The outcome of the proposed studies will be immediately relevant to the design of human trials. ..
  45. Proteomic Markers for ALS
    Jonathan Glass; Fiscal Year: 2008
    ..These candidate biomarkers will be tested for their sensitivity and specificity for disease in plasma and spinal fluid samples from mice and people with ALS. [unreadable] [unreadable] [unreadable]..
  46. CTLA-4 Inhibition and Autoimmunity in Melanoma
    Jeffrey Weber; Fiscal Year: 2008
    ..abstract_text> ..
  47. ITEM BANKING AND CAT FOR QUALITY OF LIFE OUTCOMES
    David Cella; Fiscal Year: 2008
    ..We will also monitor treatment/management changes, and evaluate acceptability of computer assessments and the perceived benefits of the recommendations. ..
  48. NAAG PEPTIDASE AND NEURONAL FUNCTION
    JOSEPH NEALE; Fiscal Year: 2008
    ..The influence of elevated NAAG levels in vivo, obtained by inhibition of NAAG peptidase activity, will be tested in rat brain and spinal cord and in transgenic mice expressing GLT-1-GFP and GLAST-GFP fusion proteins. ..
  49. Pain facilitation via neuron-to-glia signaling
    Linda Watkins; Fiscal Year: 2009
    ..Understanding this key step between neural activation &glial activation may have implications for developing new approaches for pain control. ..
  50. Optoid Analgesics: Modulation of Trigeminal & Spinal Glial Activation
    Linda Watkins; Fiscal Year: 2010
    ..If successful, these studies will lead to development of novel adjunct therapies for improving clinical pain control by controlling the negative consequences of opioid-induced glial activation. ..
  51. Cyclooxygenase Pathway and Diabetic Neuropathy
    Rodica Pop Busui; Fiscal Year: 2005
    ..abstract_text> ..
  52. HIV Neuroprotection Workshop
    Joseph Berger; Fiscal Year: 2004
    ..The proposed conference is the first of its kind to highlight neuroprotection in HIV CNS and PNS disorders. By coupling this meeting with the International Symposium on Neurovirology this synergy can be exploited. ..
  53. VISUALIZING DIABETIC FEET TO OPTIMIZE ORTHOTIC FITTING
    Michael Mueller; Fiscal Year: 2006
    ..Experimental testing will help to keep computational models realistic and valid while three dimensional computational modeling will enhance the scientific basis of orthotic design and testing. ..
  54. OspA and autoimmunity in chronic Lyme disease
    Armin Alaedini; Fiscal Year: 2007
    ..Identification of specific immune reactivity to an autoantigen might also be useful as a diagnostic marker and for monitoring of disease activity in affected patients. [unreadable] [unreadable] [unreadable]..
  55. Methods Development for Studying Dorsal Spinal Cord Glia
    Linda Watkins; Fiscal Year: 2005
    ..These new methods will then undergo initial assessments, in terms of functional characterization & receptor expression of the isolated astrocytes & microglia. ..
  56. Axonal Mechanical Sensitivity in Neuritis
    Geoffrey Bove; Fiscal Year: 2006
    ..These experiments promise to increase our knowledge of the mechanisms of chronic pain related to neuritis and nerve injury. [unreadable] [unreadable] [unreadable]..
  57. Feline Model of Neuropathy associated with anti-MAG/SGPG antibodies
    AMJAD ILYAS; Fiscal Year: 2007
    ..These studies may lead to the development of a feline model of anti-MAG/SGPG neuropathy that closely resembles the human disorder [unreadable] [unreadable] [unreadable] [unreadable]..
  58. Clinical Activity of 17-AAG in Lymphoma
    Anas Younes; Fiscal Year: 2007
    ..In Aim 3 we will correlate the biologic effects of 17-AAG and clinical response in patients with relapsed MCL, ALCL, and HL. [unreadable] [unreadable] [unreadable]..
  59. Osteopuncture for OA-Associated Knee Pain & Disability
    Debra Weiner; Fiscal Year: 2005
    ..In addition, mechanisms of action will be explored, and the impact of osteopuncture on health care costs determined. ..
  60. Mediators of Functional Hyperemia and Its Dysregulation in Post-Traumatic Brain
    Maiken Nedergaard; Fiscal Year: 2010
    ....
  61. CORTICAL MODULATION OF PAIN BEHAVIOR
    Luc Jasmin; Fiscal Year: 2002
    ..The clinical implications of loss of dopaminergic inhibition of the cerebral cortex include central pain syndromes such as those reported in Parkinson's disease and in patients treated with neuroleptic drugs. ..
  62. Schwann Cell Spinal Remyelination in the Rat
    PETER OHARA; Fiscal Year: 2006
    ..abstract_text> ..
  63. SPINAL MOTOR CONDUCTION AND RECOVERY AFTER HUMAN SCI
    Blair Calancie; Fiscal Year: 2009
    ..A slow-release formulation the K-channel blocker 4-aminopyridine will be tested for its effects on conduction in some cases. ..
  64. BODY WEIGHT SUPPORTED AMBULATION TRAINING AFTER SCI
    Blair Calancie; Fiscal Year: 2004
    ..abstract_text> ..
  65. Critical Research Issues in Essential Tremor
    Rodger Elble; Fiscal Year: 2005
    ..We believe that such conferences are the best way to build and maintain momentum and interest in ET research. ..
  66. Macrophages, HAART, and HIV dementia in Thailand
    Victor Valcour; Fiscal Year: 2006
    ..Given this unique cohort, we further intend to use proteomics to generate important molecular markers that predict M/M/phi response to HAART and that distinguish HAD in HAART-treated compared to HAART-naive individuals. ..
  67. BETTER ANTIRETROVIRAL ADHERENCE: HIV+ AMPHETAMINE USERS
    J Atkinson; Fiscal Year: 2003
    ....
  68. MACROPHAGE RECRUITMENT IN NERVOUS SYSTEM INJURY & REPAIR
    John Griffin; Fiscal Year: 2001
    ..Such animals will provide the ideal system in which to test the possibility that CNS regeneration will be substantially improved by permitting macrophage recruitment. ..
  69. EXERCISE EFFECTS ON QUALITY OF LIFE IN CANCER PATIENTS
    Kerry Courneya; Fiscal Year: 2001
    ..Fitness will be re-assessed immediately after the intervention period. ..
  70. Management of Chronic Pain in Rehabilitation Medicine
    Mark Jensen; Fiscal Year: 2006
    ..A Scientific Core will provide scientific direction, project coordination, data collection and management, statistical support, and shared scientific expertise. ..
  71. Synaptic change in cingulate cortex after amputation
    Min Zhuo; Fiscal Year: 2006
    ..This information will provide a potential neuronal basis for understanding phantom limb sensation and phantom pain. ..
  72. Hereditary spastic paraplegia linked to chromosomes 8q
    Peter Hedera; Fiscal Year: 2006
    ..I will characterize the phenotype of transgenic animals. The study of a transgenic animal model will further enhance current state of knowledge about the pathophysiology of HSP and axonal degeneration. ..